Shots:
- Tiziana has completed its clinical study in Brazil assessing nasally administered Foralumab either alone or in combination with orally administered dexamethasone in COVID-19 patients
- The study enrolled 39 patients with mod. to sev. COVID-19 who did not require the use of a ventilator at the beginning of the study with anticipated results available in Jan’2021
- The 1EPs of the study was safety of the treatment while the 2EPs were to evaluate the effect on disease severity symptoms, nasal tolerance, sense of smell, and biomarkers for disease progression. Anecdotal feedback from Foralumab-treated patients was positive suggesting that the treatment was well-tolerated
Click here to read full press release/ article | Ref: Tiziana | Image: Share Talk
The post Tiziana Completes Clinical Trial of Nasally Administered Foralumab for COVID-19 in Brazil first appeared on PharmaShots.
